Medico Intercontinental Ltd
Medico Intercontinental Ltd Live Price Chart
Medico Intercontinental Ltd Technicals
| 20 Day | ₹ 36.541 |
| 50 Day | ₹ 35.804 |
| 100 Day | ₹ 35.759 |
| 200 Day | ₹ 37.413 |
| 20 Day | ₹ 37.362 |
| 50 Day | ₹ 34.595 |
| 100 Day | ₹ 35.069 |
| 200 Day | ₹ 36.566 |
Medico Intercontinental Ltd Performance
| Previous Close | ₹ 34.96 |
| High | ₹ 36.45 |
| Volume | 404 |
| 52W Range | ₹ 26 - ₹ 50 |
| Open | ₹ 36.45 |
| Low | ₹ 33.5 |
| Market Cap | ₹ 32 Cr |
Medico Intercontinental Ltd Fundamentals
| ROCE | 7.980 |
| P/E Ratio | 15.460 |
| P/B Ratio | 0.870 |
| Industry P/E | 0.870 |
| Debt to Equity | 39.828 |
| ROE | 5.595 |
| EPS | 2.230 |
| Dividend Yield | 0.000 |
| Book Value | 39.810 |
| Face Value | 10.000 |
Medico Intercontinental Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 67.6375 | 44.4534 | 49.225 | 39.4264 | 41.1864 |
| Total Expenses | 64.062 | 41.829 | 46.8459 | 37.5984 | 39.5263 |
| Profit After Tax | 2.5658 | 1.897 | 1.7049 | 1.312 | 1.195 |
Medico Intercontinental Ltd Shareholding Pattern
| Promoter Holdings | 57.145 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 34.860 % |
| Others - | 7.995 % |
About Medico Intercontinental Ltd
History of Medico Intercontinental Ltd
Medico Intercontinental Limited, formerly known as Intercontinental Leasing & Finance Company Limited was incorporated on August 14, 1984 in Ahmedabad, India. The Company changed its name to 'Medico Intercontinental Limited' in December, 2018. The Company is involved in trading of pharmaceutical products. The Company is also providing a platform to all research based bio-pharmaceutical companies reaching their novel and innovative therapies to every part of the globe. From helping people obtain their medications to using cutting-edge scientific technology to discover new treatments, Medico's entrepreneurial spirit, teamwork-oriented culture and commitment to rare diseases create a unique platform for transforming patient outcomes. The Company's commitment to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first across the continents. The Company entered into agreement with Medico Lab and made it a Joint Venture in the F.Y. 2024-25. ...
